Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterized by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.

Abstract: The present invention provides for methods of measuring levels of micro RNAs for the diagnosis, treatment and/or monitoring the progression of post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI) in a subject having or suspected of having PTSD and/or TBI. The methods, in general comprise measuring levels of at least one of miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p, miR-463* and miR-674* is a sample from a subject suffering from or suspected of having PTSD and/or TBI.

Abstract: The invention described in the application relates to a long non-coding RNA expressed in cancer. The invention thus provides methods and compositions for evaluating levels of the long non-coding RNA to assess the aggressiveness of a cancer and for modulating levels of the long non-coding RNA.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: A method of retrieving fetal cells from an endocervical sample by removing the mucus from the endocervical sample by disassociating fetal cells and maternal cells in the endocervical sample; and isolating disassociated fetal cells from other cells in the endocervical sample. Also provided is a method of retrieving fetal cells from an endocervical sample, by obtaining a mixture of disassociated cells prepared by the above method, treating the cells with a fetal-specific antibody, identifying cells that have bound to the fetal-specific antibody, and isolating the identified cells. The disassociated cell prepared by the above method can be analyzed and used for a variety of purposes including, but not limited to, the identification of fetal cells among cervical cells, determination of fetal cell density to predict high risk pregnancy, genetic analysis of fetal cells, and determination of growth factor or other biomarker expression to predict obstetrical disorders.

Abstract: Methods of isolating and assaying fetal extravillous trophoblast cells, including assays of RNA of the fetal extravillous trophoblast cells according to aspects of the disclosure include obtaining a maternal endocervical sample containing fetal extravillous trophoblast cells from a pregnant subject; fixing the maternal endocervical sample in an aldehyde fixative, removing fetal extravillous trophoblast cells from the maternal endocervical sample thereby producing isolated extravillous trophoblast cells, isolating and assaying RNA from the fetal extravillous trophoblast cells.

Abstract: A Sidt1 gene controlling a determinate growth habit of sesame, the gene having a length of 1809 bp and including four exons and three introns. The Sidt1 gene is located on the fourth chromosome of sesame and in an 18.0-19.2 cM interval of the eighth linkage group on an SNP genetic map of sesame. The DNA sequence of the Sidt1 gene is represented by SEQ ID NO. 1. A cDNA sequence of the Sidt1 gene has a length of 531 bp and encodes 176 amino acids, and the cDNA sequence is represented by SEQ ID NO. 2. An SNP molecular marker Sidt27-1 of the Sidt1 gene has a length of 92 bp and is located at a base sequence from 378 to 469 of the Sidt1 gene, and a DNA sequence of the SNP molecular marker Sidt27-1 is represented by SEQ ID NO. 3.

Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.

Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD8 positive subpopulations of a mammal, wherein said method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD8 beta and CD8 alpha cell specific bisulfite convertibility gene region according to SEQ ID No. 1 and 2, wherein a bisulfite convertibility of at least one CpG position in said gene regions is indicative for a CD3+CD8+ and/or CD3+/?CD8+ cell. The analyzes according to the invention can identify CD3+CD8+ and/or CD3+/?CD8+ cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells.

Abstract: The present invention provides methods of detecting c-KIT-dependent-melanoma for diagnostic and prognostic purposes. The invention further provides methods of treating such melanoma by inhibiting c-KIT.

Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Abstract: A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock genes, each in the plasma sample at the first time point and in the plasma sample at the second time point. Then determining that a first treatment is effective or ineffective for the patient when a correlation of the gene expression level of the set of core clock genes, the first set of peripheral clock genes, and the second set of peripheral clock genes, and treating the patient accordingly.

Abstract: The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

Abstract: Methods, probes and kits for diagnosing malignant melanoma and prognosing metastasis thereof in a patient.

Abstract: Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRa1 CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.

Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).

Abstract: The present invention discloses the identification of a fibrosis susceptibility gene locus, the IL22RA2 gene locus, which can be used for detecting predisposition to, diagnosis and prognosis of fibrosis as well as for the screening of therapeutically active drugs. The invention further provides a method for determining the likelihood of a patient affected with a viral infection to respond to a treatment with an antiviral agent and/or an interferon, which method comprises determining alteration in IL22RA2 gene locus or in IL22RA2 expression or IL22RA2 protein activity in a biological sample of the patient.